Intra-Cellular Therapies, Inc. Overview
Pro stress-test →Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system. In early 2025, Johnson & Johnson announced the completion of its acquisition of Intra-Cellular Therapies for approximately $15 billion, with J&J acquiring all outstanding shares for $132.00 per share in cash.
Strategic Profile
Pro stress-test →The company's product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder. CAPLYTA is noted for its unique mechanism of action that modulates dopamine, serotonin, and glutamate levels simultaneously, with analysts projecting that peak sales could exceed $5 billion annually.
Competitive Landscape
Pro stress-test →The success of Intra-Cellular Therapies highlighted a shift in the neuropsychiatry market, as unlike traditional medications with heavy side-effect profiles, ITCI's approach to intracellular signaling aimed for higher efficacy with fewer metabolic complications. Main competitors in the antipsychotic and bipolar depression space include Janssen (part of J&J parent company), Otsuka/Lundbeck, and Allergan in the neuropsychiatric therapeutics segment.
Industry Context
Intra-Cellular Therapies, Inc. operates in Biopharmaceutical - CNS/Neuropsychiatric Therapeutics.
Key facts
Founded: 2002 · Headquarters: New York, US · Employees: N/A · Revenue: N/A · Market cap: N/A